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A 36-years-old man on phenytoin, levetiracetam, and sodium valproate presented with acute confusion. Routine investigations
includingserumvalproateandphenytoin concentrationwere normal.Hisserumammoniaconcentrationwasraised.Hisvalproate
was held and 2 days later he recovered with concordant normalisation of serum ammonia concentration. Urea acid cycle
disorder was ruled out, and a diagnosis of valproate induced hyperammonemic encephalopathy (VHE) was made. Asymptomatic
hyperammonemia occurs in 15–50% of valproate-treated patients, and while the true incidence of VHE is not known, it is a
recognized complication of sodium valproate treatment. VHE typically presents acutely with impaired consciousness, lethargy,
and vomiting.Valproate concentrations maybe in the therapeutic range, and liver function tests are typically “normal.”Treatment
for VHE consists of ceasing valproate and providing supportive care. Some have advocated carnitine replacement.
Patients with valproate induced hyperammonemic Enceph-
alopathy (VHE) may present with impaired consciousness,
lethargy or increased seizure frequency. These patients may
have normal liver function tests and plasma valproate
concentrationleadingtotheattending physicianoverlooking
the diagnosis of VHE.
A 36-year-old man presented with acuteconfusion about
20 hours after an alcohol binge. Although he had long
standing partial epilepsy, his partner had not observed any
seizures and said this was unlike usual post ictal state.
His regular medications were phenytoin 300mg twice daily,
levetiracetam 500mg twice daily, and sodium valproate 1.5g
mane 2g NOCTE. He had splenectomy 3 years previously
foridiopathicthrombocytopeniawithnormalplateletcounts
since then. He was a current smoker and an alcohol binge
drinker once or twice a month.
Findings at admission included normal physical exam-
ination, blood count, electrolytes, liver function tests, CRP,
urinalysis, chest radiograph, ECG and head CT scan. Plasma
ethanol < 0.01g/dL excluded acute alcohol intoxication and
urine toxicology screen was negative. Plasma valproate
was 52.9mg/L (range 50–100mg/L) and plasma pheny-
toin 13.8mg/L (range 10–20mg/L). Serum ammonia was
high—284umol/L (<50umol/L). Valproate was withheld,
his symptoms resolved over 24 hours, and on day 3 the
serum ammonia was 36umol/L. Screening for urea cycle
disorders was negative. A diagnosis of valproate induced
hyperammonemic encephalopathy (VHE) was made.
The typical presentation of VHE is impaired con-
sciousness and lethargy. Focal neurological symptoms and
increased seizure frequency may be present [1]. The inci-
dence of VHE is not known, but asymptomatic increases in
serum ammonia are seen in 16%–52% of patients receiving
valproate therapy [2]. VHE can occur with normal liver
function tests and plasma valproate concentration [3].
Ammonia is eliminated by theurea cyclewhose ﬁrst rate-
limiting step is mediated by carbamylphosphate synthetase1
(CPS1). CPS1 in turn is activated by N-acetylglutamate.
The metabolism of valproate by mitochondrial oxidation
produces propionyl Co-A and valproyl Co-A, which inhibit
N-acetylglutamate synthetase with consequent depletion of
N-acetylglutamate. This leads to the inhibition of CPS1
resulting in decreased clearance of ammonia [4, 5]. Another
mechanism thought to play a role is the reduction of hepatic
carnitinelevelsbyvalproate.Deﬁciencyofcarnitineresultsin
decreased beta-oxidation of fatty acids, which in turn results2 Case Reports in Medicine
in reduced levels of acetyl Co-A. Acetyl Co-A is a substrate
for theN-acetylglutamatesynthetase mentioned above.Thus
the decrease in acetyl Co-A ultimately disrupts the urea cycle
resulting in ammonia accumulation [6].
Treatment for VHE includes supportive care and with-
holding valproate. L-carnitine replacement is sometimes
used [7, 8]. Extremely high concentrations of ammonia
may warrant dialysis [9]. The diagnosis of VHE may be
overlooked when the serum valproate concentration and
liver function tests are within expected ranges. Physicians
should be alert to this potential complication of valproate
and measure serum ammonia in patients with alterations in
mental status or unexplained increase in seizure frequency.
Adjustment of dose or withdrawal of valproate may be
necessary in the symptomatic patient in whom altered
mental status is not due to seizure activity.
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